Breast Cancer Cell Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 1 of 3: Cell count and normalized growth rate inhibition values. - Dataset (ID:20256)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Replicate | Seeding Density | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | 0 | uM | 8 | 312.50 | 180.33 | 239.00 | 311.75 | 0.7666 | 0.4285 | |
| SK-BR-3 | 0 | uM | 8 | 312.50 | 180.33 | 201.00 | 311.75 | 0.6448 | 0.1473 | |
| SK-BR-3 | 0 | uM | 8 | 312.50 | 180.33 | 201.00 | 311.75 | 0.6448 | 0.1473 | |
| SK-BR-3 | Linsitinib | 19.9526 | uM | 8 | 312.50 | 180.33 | 198.00 | 311.75 | 0.6351 | 0.1256 |
| SK-BR-3 | Linsitinib | 3.1623 | uM | 8 | 312.50 | 180.33 | 228.00 | 311.75 | 0.7314 | 0.3458 |
| SK-BR-3 | Lapatinib | 0.0033113 | uM | 8 | 312.50 | 180.33 | 335.00 | 311.75 | 1.0746 | 1.1907 |
| SK-BR-3 | Erlotinib | 0.0033113 | uM | 8 | 312.50 | 180.33 | 418.00 | 311.75 | 1.3408 | 1.8994 |
| SK-BR-3 | Linsitinib | 0.1 | uM | 8 | 312.50 | 180.33 | 318.00 | 311.75 | 1.0200 | 1.0509 |
| SK-BR-3 | Lapatinib | 0.1 | uM | 8 | 312.50 | 180.33 | 301.00 | 311.75 | 0.9655 | 0.9131 |
| SK-BR-3 | 0 | uM | 8 | 312.50 | 180.33 | 397.00 | 311.75 | 1.2735 | 1.7162 | |
| SK-BR-3 | 17-AAG | 0.000066069 | uM | 8 | 312.50 | 180.33 | 299.00 | 311.75 | 0.9591 | 0.8970 |
| SK-BR-3 | 0 | uM | 8 | 312.50 | 180.33 | 339.00 | 311.75 | 1.0874 | 1.2239 | |
| SK-BR-3 | Linsitinib | 0.01 | uM | 8 | 312.50 | 180.33 | 462.00 | 311.75 | 1.4820 | 2.2912 |
| SK-BR-3 | 17-AAG | 0.1 | uM | 8 | 312.50 | 180.33 | 187.00 | 311.75 | 0.5998 | 0.0470 |
| SK-BR-3 | Lapatinib | 0.01 | uM | 8 | 312.50 | 180.33 | 409.00 | 311.75 | 1.3119 | 1.8206 |
| SK-BR-3 | Lapatinib | 0.31623 | uM | 8 | 312.50 | 180.33 | 190.00 | 311.75 | 0.6095 | 0.0684 |
| SK-BR-3 | 17-AAG | 0.31623 | uM | 8 | 312.50 | 180.33 | 184.00 | 311.75 | 0.5902 | 0.0258 |
| SK-BR-3 | Erlotinib | 0.1 | uM | 8 | 312.50 | 180.33 | 329.00 | 311.75 | 1.0553 | 1.1412 |
| SK-BR-3 | 0 | uM | 8 | 312.50 | 180.33 | 343.00 | 311.75 | 1.1002 | 1.2572 | |
| SK-BR-3 | Erlotinib | 19.9526 | uM | 8 | 312.50 | 180.33 | 460.00 | 311.75 | 1.4755 | 2.2732 |
| SK-BR-3 | Lapatinib | 0.031623 | uM | 8 | 312.50 | 180.33 | 270.00 | 311.75 | 0.8661 | 0.6671 |
| SK-BR-3 | Lapatinib | 0.0016596 | uM | 8 | 312.50 | 180.33 | 404.00 | 311.75 | 1.2959 | 1.7770 |
| SK-BR-3 | 17-AAG | 0.031623 | uM | 8 | 312.50 | 180.33 | 159.00 | 311.75 | 0.5100 | -0.1474 |
| SK-BR-3 | 0 | uM | 8 | 312.50 | 180.33 | 257.00 | 311.75 | 0.8244 | 0.5661 | |
| SK-BR-3 | 0 | uM | 8 | 312.50 | 180.33 | 202.00 | 311.75 | 0.6480 | 0.1545 |